Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Open Label, Multi-center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Fimepinostat (CUDC-907), a PI3K and HDAC Inhibitor, in Subjects With Refractory or Relapsed Lymphoma

NCT01742988 is registered in ClinicalTrials.gov with Curis, Inc. as lead sponsor.

NCT NCT01742988
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01742988 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Open Label, Multi-center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Fimepinostat (CUDC-907), a PI3K and HDAC Inhibitor, in Subjects With Refractory or Relapsed Lymphoma
Lead sponsor
Curis, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2012
Completion date
October 9, 2020
Enrollment
106 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

double-expressor lymphoma (del), double-hit lymphoma (dhl), high-grade b-cell lymphoma (hgbl), lymphoma, refractory diffuse large b-cell lymphoma (dlbcl), refractory lymphoma, relapsed and/or refractory diffuse large b-cell lymphoma (dlbcl), relapsed and/or refractory lymphoma, relapsed ddiffuse large b-cell lymphoma (dlbcl), relapsed lymphoma, triple-hit lymphoma (thl)